Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | TAS2R14 | Q9NYV8 | 7/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PTGES | O14684 | 2/20 | 0.38 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.38 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22553416 | 0.80 | HRH3 (0.56) | APLNRALDH1A1MAPTLMNAPOLB | |
| SCHEMBL22553445 | 0.76 | HRH3 (0.51) | APLNRTAS2R14MAPTPKMPTGES | |
| SCHEMBL22553447 | 0.75 | APLNR (0.51) | APLNRTAS2R14MAPTPKMPTGES | |
| SCHEMBL22553457 | 0.75 | APLNR (0.51) | APLNRTAS2R14MAPTPKMPTGES | |
| SCHEMBL16235820 | 0.74 | APLNR (0.65) | APLNRTAS2R14PTGESTAS2R8CXCR3 | |
| SCHEMBL22553433 | 0.73 | APLNR (0.46) | APLNRTAS2R14PTGES | |
| SCHEMBL13166684 | 0.73 | APLNR (0.63) | APLNRTAS2R14PTGESTAS2R8CXCR3 | |
| SCHEMBL6122831 | 0.72 | APLNR (0.71) | APLNRALDH1A1TAS2R14PTGESTAS2R8 | |
| SCHEMBL13166683 | 0.72 | CASP3 (0.55) | APLNRALDH1A1KMT2A | |
| SCHEMBL20189329 | 0.71 | APLNR (0.44) | APLNRTAS2R14MAPTPKMPTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773058-B2 | Sulfonamide carboxamide compounds | INFLAZOME LIMITED (IE) | 2023-10-03 | — | — | US | disclosed |
| US-11773058-B2 | Sulfonamide carboxamide compounds | INFLAZOME LIMITED (IE) | 2023-10-03 | — | — | US | disclosed |
| US-20200331850-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2020-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773058-B2 | Sulfonamide carboxamide compounds | NLRP3, NOD1, NLRP1 | APLNR 1240/4885ALDH1A1 1414/4885TAS2R14 345/4885 |
| US-20200331850-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | NLRP3, NOD1, NLRP1 | APLNR 1280/4885ALDH1A1 1729/4885TAS2R14 380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.